mRNA Delivery for CAR-T Therapy: From Concept to In Vivo Application

CAR-T therapy has transformed the treatment landscape for certain hematologic malignancies, demonstrating remarkable clinical success in patients with relapsed or refractory cancers. However, despite its promise, conventional CAR-T therapy still faces substantial barriers in manufacturing, cost, and accessibility.

As the field evolves, researchers and biotech innovators are increasingly exploring mRNA delivery for CAR-T therapy as a faster, more flexible, and potentially safer alternative to traditional ex vivo engineering. In particular, advances in in vivo delivery systems, including targeted lipid nanoparticles (tLNPs), are opening new possibilities for generating CAR-T cells directly inside the body.

In this article, we explore how mRNA delivery is reshaping CAR-T development, why in vivo application is attracting so much attention, and what challenges still need to be overcome.

Why Traditional CAR-T Therapy Faces Delivery and Manufacturing Challenges

Conventional CAR-T therapy typically involves multiple complex steps:

1. T cells are collected from the patient
2. The cells are genetically modified ex vivo, often using viral vectors
3. The engineered cells are expanded in specialized manufacturing facilities
4. The final CAR-T product is infused back into the patient

This process has delivered strong clinical benefit, but it also comes with clear limitations:

• Long manufacturing timelines
• High production costs
• Complex logistics and quality control
• Limited patient accessibility
• Dependence on viral vector systems

For patients with rapidly progressing disease, waiting several weeks for an autologous CAR-T product may not be feasible. These limitations have driven growing interest in non-viral and in vivo CAR-T approaches.

Figure 1：Traditional CAR-T vs In Vivo CAR-T Generation

Why mRNA Delivery Is Attractive for CAR-T Therapy

mRNA offers a compelling alternative for cell engineering because it enables transient protein expression without genomic integration. In the CAR-T setting, mRNA can be used to encode chimeric antigen receptors and deliver the CAR message directly into T cells.

This approach brings several important advantages:

• Rapid expression: mRNA enables fast protein production after delivery, which is valuable for applications requiring quick therapeutic action.
• No risk of insertional mutagenesis: Unlike integrating viral vectors, mRNA does not need to enter the genome, improving safety in many applications.
• Flexible design and screening: mRNA constructs can be quickly redesigned, making it easier to optimize CAR structure, test new targets, or evaluate combination strategies.
• Potential for scalable manufacturing: mRNA production is generally more standardized and scalable than individualized viral vector manufacturing.

Because of these advantages, mRNA delivery for CAR-T therapy is increasingly being explored as a bridge between early discovery, translational development, and future in vivo treatment models.

From Ex Vivo Engineering to In Vivo CAR-T Generation

Early work with mRNA in CAR-T therapy focused mainly on ex vivo electroporation, where T cells are isolated, transfected with CAR-encoding mRNA, and then reinfused into patients. This strategy demonstrated that mRNA could successfully drive CAR expression, but the effect was temporary and still relied on complicated cell-handling workflows.

The next major step is in vivo CAR-T generation.

Instead of engineering T cells outside the body, the goal is to deliver nucleic acids directly to immune cells in vivo, allowing the patient’s own T cells to transiently express CAR molecules after systemic administration. If successful, this strategy could reduce manufacturing burden and dramatically simplify treatment.

This is where advanced delivery platforms become essential.

The Central Challenge: Delivering mRNA to T Cells In Vivo

Although mRNA is powerful, delivering it effectively to T cells in vivo is extremely challenging.

T cells are among the hardest cell types to transfect because:

• They are less naturally permissive to nucleic acid uptake
• They circulate dynamically rather than remaining in one fixed tissue site
• Delivered mRNA must be protected from degradation in the bloodstream
• Delivery vehicles must avoid off-target accumulation in organs such as the liver
• Efficient cytosolic release is required for translation

In other words, successful in vivo CAR-T generation depends not just on the mRNA itself, but on whether the delivery system can bring that payload specifically and efficiently to T cells.

Current Delivery Approaches and Their Limitations

Several delivery strategies have been explored for CAR-related cell engineering, but each has limitations.

• Viral vectors

Viral vectors have historically been the most established tools for T-cell engineering. They can support stable gene transfer, but they also come with challenges such as complex manufacturing, regulatory burden, payload constraints, and potential safety concerns related to genome integration.

• Electroporation

Electroporation is widely used for ex vivo mRNA delivery into T cells. It can achieve relatively high transfection efficiency in controlled lab settings, but it is not an in vivo delivery solution and still requires cell isolation and reinfusion.

• Conventional LNPs

Lipid nanoparticles have become a leading platform for nucleic acid delivery, especially for liver-targeted applications. However, standard LNP formulations often show preferential accumulation in the liver, making them less suitable for selective T-cell targeting without additional engineering.

This limitation highlights an important point: not all LNPs are designed for immune-cell-specific delivery.

Why Targeted LNPs Matter for In Vivo CAR-T Applications

To make in vivo mRNA delivery for CAR-T therapy practical, delivery systems must do more than encapsulate RNA. They must also direct the payload toward the right cell population.

Targeted lipid nanoparticles (tLNPs) are designed to address this challenge by incorporating targeting features that improve cell selectivity and biodistribution. For CAR-T applications, tLNP systems aim to:

• Enhance delivery to T cells or specific immune subsets
• Reduce off-target uptake
• Improve functional expression of CAR constructs in vivo
• Support transient, controllable protein expression
• Provide a non-viral route for immune cell engineering

This targeted approach is especially important in immunotherapy, where delivery precision can strongly influence both efficacy and safety.

As a result, tLNP-based mRNA delivery is emerging as a promising strategy for enabling non-viral CAR-T and broader in vivo cell therapy applications.

From Concept to Application: What an Effective mRNA CAR-T Delivery Platform Needs

For researchers developing next-generation CAR-T strategies, an effective in vivo mRNA delivery platform should ideally offer several key capabilities

• Efficient encapsulation of CAR-encoding mRNA

The system must protect mRNA integrity and maintain payload quality during formulation and delivery.

• Selective targeting to T cells

Cell specificity is crucial for reducing unwanted expression in non-target tissues.

• High intracellular delivery efficiency

Even if particles reach the target cell, they must still enter the cell and release mRNA into the cytoplasm.

• Transient but functional CAR expression

For some therapeutic settings, transient CAR expression may offer safety and dosing advantages, especially in early-stage research and iterative optimization.

• Scalable and reproducible formulation

A research-to-translation platform should support both discovery studies and future development needs.

These design requirements explain why the field is shifting from general-purpose delivery systems toward more specialized, application-driven nanoparticle platforms.

Figure 2：mRNA delivery for CAR-T

How Targeted mRNA Delivery Supports the Future of CAR-T Therapy

The future of CAR-T therapy may not depend solely on improving ex vivo manufacturing. It may also depend on rethinking how CAR constructs are delivered in the first place.

By combining mRNA technology with targeted LNP delivery, researchers may be able to move from labor-intensive cell manufacturing toward more streamlined, programmable, and potentially repeatable in vivo therapies.

This shift could offer major benefits:

• Faster therapeutic deployment
• Lower production complexity
• Reduced dependence on viral vectors
• Better accessibility for broader patient populations
• Greater flexibility for immunotherapy innovation

While challenges remain, the direction is clear: mRNA delivery is becoming a key enabling technology for next-generation CAR-T therapy, and targeted in vivo delivery systems will likely play a central role in that transition.

Conclusion

CAR-T therapy has already changed cancer treatment, but its full potential may only be realized when delivery becomes simpler, faster, and more scalable.

mRNA delivery for CAR-T therapy provides a promising path forward by enabling non-viral, transient, and flexible cell engineering. However, unlocking its potential in vivo requires advanced delivery solutions capable of reaching T cells with precision.

This is why targeted LNP platforms are gaining increasing attention. By improving cell-specific delivery and supporting in vivo CAR expression, they may help bridge the gap between concept and practical application in next-generation immunotherapy.

If your work focuses on mRNA delivery, targeted LNP development, or in vivo CAR-T research, choosing the right delivery platform is critical to accelerating discovery and improving translational success.

Levostar’s Approach

At Levostar, we focus on developing custom mRNA and targeted LNP delivery solutions to support advanced therapeutic research, including:

Custom mRNA synthesis for CAR constructs

Targeted LNP formulation for immune cell delivery

Optimization for in vivo gene delivery applications

👉 Learn more about our technology:

• mRNA synthesis services
• Targeted LNP delivery platforms

Looking for a Custom Solution?

If you are exploring mRNA delivery or targeted LNP systems for your research, feel free to contact our team or find a local distributor for support.